Table 1.
Demographics of all patients on antimalarials and subset on quinacrine
| Total on Antimalarials N = 538 N (%) |
Quinacrine Users N = 316 N (%) |
Percentage of Quinacrine Users per Demographic Category % |
||
|---|---|---|---|---|
| Mean Age | 52.3 | 52.9 | ||
| Gender | ||||
| Female | 458 (85.1) | 273 (86.4) | 59.6 | |
| Male | 80 (14.9) | 43 (13.6) | 53.8 | |
| Race | ||||
| Black | 125 (23.2) | 76 (24.1) | 60.8 | |
| White | 376 (69.9) | 217 (68.7) | 57.7 | |
| Asian | 16 (3.0) | 7 (2.2) | 43.8 | |
| Other | 18 (3.3) | 14 (4.4) | 77.8 | |
| Unknown | 3 (0.6) | 2 (0.6) | 66.7 | |
| Ethnicity | ||||
| Hispanic | 15 (2.8) | 10 (3.2) | 66.7 | |
| Not-Hispanic | 519 (96.5) | 303 (95.9) | 58.4 | |
| Unknown | 4 (0.7) | 3 (0.9) | 75 | |
| Smoking History | ||||
| Never | 301 (55.9) | 158 (50) | 52.5 | |
| Current | 101 (18.8) | 65 (20.6) | 64.4 * | |
| Past | 134 (24.9) | 91 (28.8) | 67.9 * | |
| Unknown | 2 (0.4) | 2 (0.6) | 100 | |
| Disease Type | ||||
| CLE | 368 (68.4) | 222 (70.3) | 60.3 | |
| Dermatomyositis | 170 (31.6) | 94 (29.7) | 55.3 | |
| CLE subtype | ||||
| Discoid Total | 162 (30.1) | 114 (21.2) | 70.4 | |
| Discoid + SLE | 64 (11.9) | 53 (16.8) | 84.7 | |
| Discoid + LP | 6 (1.1) | 6 (1.9) | 100 | |
| LET Total | 24 (4.5) | 12 (3.8) | 50 | |
| LET +SLE | 1 (0.2) | 1 (0.3) | 100 | |
| LP | 4 (0.7) | 1 (0.3) | 25 | |
| Hypertrophic | 3 (0.6) | 2 (0.6) | 66.7 | |
| Chilblains | 2 (0.4) | 2 (0.6) | 100 | |
| Lupus Pernio | 1 (0.2) | 1 (0.3) | 100 | |
| SCLE Total | 70 (16.9) | 41 (12.9) | 58.6 | |
| SCLE + SLE | 19 (3.5) | 10 (3.2) | 52.6 | |
| ACLE Total | 12 (2.2) | 4 (1.3) | 33.4 | |
| ACLE + SLE | 11 (2.0) | 4 (1.3) | 36.7 | |
| Total SLE | 64 (11.9) | 41 (13.0) | 64.1 | |
| History of HCQ a | 534 (99.3) | 312 (98.7) | 58.4 | |
| History of CQ b | 98 (18.2) | 85 (26.9) | 86.7 | |
*
Quinacrine users are significantly more likely to have smoking history than non-users, p = 0.0045.
a
HCQ = hydroxychloroquine,
b
CQ = Chloroquine